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ABSTRACT
Compositions containing as the active ingredient a spin

trapping reagent, preferably ot-phenyl butyl nitrone (PBN)
or spin-trapping derivatives thereof, in a suitable pharma
ceutical carrier for administration to a patient are disclosed

for treating or preventing symptoms associated With aging or
other conditions associated With oxidative tissue damage.
Other spin-trapping agents can also be used, such as 5,5

dimethyl pyrroline N-oxide (DMPO) or ot-(4-pyridyl
1-oxide)-N-tert-butylnitrone (POBN), and other spin
trapping derivatives thereof. These compositions and meth
ods are useful in the treatment of age-related disorders,

OTHER PUBLICATIONS

pre-surgical and/or pre-anesthetic preparation or administra

Bolli et al., J. Clin. Invest. 82, pp. 476,485 (Aug. 1988).
Chiu et al., Transplantation Proceedings, vol. XIX, No. 1,

tion of chemotherapeutic agents, and in the treatment of
disorders or trauma of the brain, cardiovascular system, and
lymphatic system. Studies in animals demonstrate that
administration of compound for a tWo Week period reduces

pp. 1077—1079 (Feb. 1987).
Hamburger et al., Circulatory Shock, 29, pp. 329—334

(1989).
Hearse et al., J. Mo. Cell, Cardiol., 20, pp. 223—233 (1988).
Hearse et al., Circulation Research, vol. 60, No. 3, pp.

375—383 (1987).

the level of oxidiZed brain enzymes to normal and restores
memory to the same level as tested in young control animals.
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METHOD OF TREATMENT OF
CONDITIONS ASSOCIATED WITH
OXIDATIVE TISSUE DAMAGE

functional and less able to maintain the speci?ed role of
those cells in that particular area of the central nervous

system. While this hypothesis has been suggested by several
investigators, there are no reports of substantial investiga
tions in Which alterations in the oxidiZed protein burden of

This is a continuation of application Ser. No. 08/365,548,
?led Dec. 28, 1994, now US. Pat. No. 5,578,617, Which is
a divisional of application Ser. No. 08/027,559, ?led Mar. 5,

the central nervous system Was manipulated and correlated
With a functional outcome on the part of the animal. Such an

1993, now US. Pat. No. 5,405,874, Which is a continuation

approach, if truly associated With brain dysfunction, Would

of application Ser. No. 07/589,177, ?led Sep. 27, 1990, noW
abandoned, Which is a continuation-in-part of application

provide a basis for reversing the age related neuronal de?cit
of cells that are still viable. Thus, such an approach is
targeted at cells Which are marginally functional but still
viable.
It is therefore the object of the present invention to
provide composition and methods for the use in preventing
or reversing age related functional de?cits.
It is further the object of the present invention to provide

10

Ser. No. 07/422,651, ?led Oct. 17, 1989, now US. Pat. No.

5,025,032.
BACKGROUND OF THE INVENTION

The present invention is a method and compositions

15

containing spin trapping agents for the treatment of age
related dysfunctions and other conditions arising from oxi

composition and methods for use thereof Which are useful in

dative damage.
Age related changes in central nervous system function
have generally been associated With the loss of cells, a
Widening of lateral ventricles and de?cits in short term
memory. The precise mechanisms of functional changes as
a result of aging, or other diseases associated With aging,

have not generally been agreed upon.
Several mechanisms for the generation of oxidiZed mate
rial in the brain have been proposed. In particular, transition
metals, especially iron and copper, have been suggested as
mediating aspects of this oxidation. A marked reduction in
certain neurotransmitter receptor systems has been associ
ated With increased oxidation of proteins. For example,
decreases in muscarinic receptors and other cholinergic

preventing and reversing cognitive de?cits associated With
infection or in?ammation.
20

It is another object of the present invention to provide

composition and methods reducing post traumatic cognitive

dysfunction.
SUMMARY OF THE INVENTION
25

Compositions containing as the active ingredient a spin

trapping reagent, preferably ot-phenyl butyl nitrone (PBN),
30

or spin-trapping derivatives thereof, in a suitable pharma
ceutical carrier for patient, are disclosed for treating or
preventing symptoms associated With aging or other condi

tions associated With oxidative tissue damage. The preferred
PBN compositions have the folloWing general formula:

systems have been characteriZed as they relate to alterations
in functions in AlZheimers disease. It has also been hypoth

esiZed that aging is associated With multiple minor periods
of ischemia (multi-infarct conditions or transient ischemia
attacks) Which, over a period of time, may give rise to the

H

O'

\

35
X

/

+\

Y

Wherein:

production of oxidiZed protein.
Changes associated With ischemic brain disease have been
proposed to be the result of alterations in calcium

N/

—/<OR>H
40

X is phenyl or \

/

, Wherein R is H,

disposition, increase in excitoxic neurotransmitter release,
production of free radicals and the attendant acidosis that
results in an increase in the loosely related metals in the cell
that are catalytic for the generation of oxygen free radicals.
These changes are largely limited to neuronal elements.

O

Z 1':
—

—, or

0

Z

CH—N/\

; or

—

45

,

Y

and n is a Whole integer from 1 to 5; or

Reactive glia have been demonstrated, hoWever, they are

mostly associated With postneuronal damage.
The treatment of age related dementias have been largely

limited by the inability to develop an appropriate model for
the study of this condition. This is due to the fact that aging
is a very complicated condition Which is dif?cult to model,

Y is tert-butyl group that can be hydroxylated or acetylated on

especially With the lack of speci?c information associated

one or more positions; phenyl; or

With the functional and biochemical basis of human age
related dementias. The use of animal models has largely

/

depended upon model systems used in brain studies, Where

55

the brains are not truly senescent, or the use of senescent

ll

animals, With little understanding of the origin of the senes

wherein W is—C—CH3, —NH—C—Z—, —C—OZ, or Z; and

cence or, in some cases, the inability to demonstrate truly

Z is a C1 to C5 straight or branched alkyl group.

functional senescence.

The demonstration in a variety of systems, both neural
and nonneural, that there is an age related enhancement of
the level of oxidiZed protein in tissue gives rise to the
possibility that age related dysfunctions in the central ner
vous system may be associated With the build-up of oxidiZed
proteins and oxidiZed macromolecules Within neurons
throughout the central nervous system. The hypothesis is
that cells Which have a buildup of oxidiZed protein are less

OW

60

Other spin-trapping agents can also be used, such as

5,5-dimethyl pyrroline N-oxide (DMPO) or ot-(4-pyridyl
1-oxide)-N-tert-butyinitrone (POBN), and other spin
65

trapping derivatives thereof.
In the preferred embodiment, the compositions are admin
istered one to tWo times daily by oral administration, at a

6,107,315
3

4

dosage equivalent to between one and ten milligrams PBN/
70 kg of human body Weight. Studies in animals demon

gerbils treated for fourteen days and tested at 1, 3, 7 and 14
days post dosing. FIG. 4B is the time related decrease in

strate that administration of compound for a tWo Week

cortical glutamine synthetase (GS) activity after termination

period reduces the level of oxidiZed brain enZymes to

of tWice daily injections of PBN. FIG. 4C demonstrates the
time related decrease in alkaline protease activity folloWing
termination of tWice daily injections of PBN. Each histo

normal and restores memory to the same level as tested in

young control animals. A signi?cant reduction in oxidiZed
proteins and memory recovery is observed as early as seven

days after initiation of treatment; levels are still comparable
to young controls one to three days folloWing cessation of
treatment, and partially reduced at seven days folloWing

10

gram is the mean 1 SE. of three subjects at each of the
indicated times. The asterisk and dashed line indicates the
old gerbil, untreated control values for each of the measures.
FIG. 5 is a graph of the eight arm radial arm maZe

cessation of treatment.
These compositions and methods are useful in the treat

performance of young or old gerbils treated With either

ment of age-related disorders, pre-surgical and/or pre

partment of the maZe With the barrier in place to limit
exploration. After the barrier Was removed, the number of
arms re-entered and the total elapsed time before all eight

saline or PBN. Gerbils Were placed into the central com

anesthetic preparation or administration of chemotherapeu
tic agents, and in treatment of disorders or trauma of the 15

brain, cardiovascular system, lymphatic system, and,
potentially, in the treatment of some viral disorders charac

arms Were entered Was recorded. Each histogram represents
the mean 1 of 18 gerbils. The animals Were administered

teriZed by oxidation of host proteins in cells infected by the

PBN tWice daily (either 10 or 32 mg PBN/kg body Weight)

virus.

for seven days and tested at the end of seven days of dosing.
DETAILED DESCRIPTION OF THE
INVENTION

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a graph of the alkaline protease activity from
gerbil cortex (% of young, three to four month old gerbil

cortex) for young gerbils (age three to four months), old
gerbils (retired breeders of tWelve to ?fteen months of age),
old gerbils that received tWice daily injections of 0.1 ml
saline/kg body Weight, and old gerbils that received tWice
daily injections of 10 mg PBN in saline/kg body Weight for

It has noW been discovered that, further to the methods
25

symptoms associated With aging, trauma, drug administra
tion and surgery, especially of the brain. As used herein, a
free radical scavenger or spin-trap reagent is a molecule that
Will form a stable complex With free radical. A free radical
carbon trap is a molecule in Which the free radical is

tWo Weeks. Protease activity Was determined using oxidiZed

protein extracted from young gerbil cerebral cortex.
FIG. 2A and FIG. 2B are graphs comparing protein

carbonyl activity (pmol/mg protein) (FIG. 2A) and

localiZed on a carbon atom or a nitrogen atom. As a result

glutamine synthetase activity (FIG. 2B) in the cerebral
cortex (neocortex) of young adult and old gerbils over days
of administration of 32 mg PBN/kg administered tWice a day

35

for one, three, seven or fourteen days. At the end of each of

the days indicated, animals Were decapitated and cerebral
cortex removed and rapidly froZen in liquid nitrogen. Pro

Currently, there are no effective, non-toxic treatments for

aging. Effectiveness has been demonstrated in animals after

gerbil cerebral cortex as a result of tWice daily administra

three subjects.
FIGS. 3A, 3B and 3C are graphs comparing changes in

of this chemical bond formation, the free radical is no longer
damaging to the cell. In combination With a pharmaceutical
vehicle suitable for administration to a patient, preferably by
oral administration, these compounds are useful in prevent

ing or reversing symptoms associated With aging, for
example, increased levels of oxidiZed proteins, decreased
enZymatic activity, and spatial and short term memory.

tein carbonyl content Was determined using the DNPH
procedure. The results demonstrate the reduction in oxida
tive damage to proteins and the loss of enZyme activity in

tion of 32 mg PBN/kg (i.p.). Each histogram is the mean of

using PBN for the treatment and prevention of ischemic
damage described and claimed in US. Ser. No. 07/422,651
?led Oct. 17, 1989, noW Reissue US. Pat. No. 35,112,
spin-trapping agents are useful in preventing or treating

as feW as seven days of administration. Effectiveness con

tinues for at least one Week after administration. Values
45
return to pretreatment levels after tWo Weeks.

protein carbonyl (pnol/mg protein) (FIG. 3A), glutamine
synthetase (FIG. 3B), and protease activity (% control)

USEFUL SPIN-TRAPPING COMPOUNDS
PBN and Derivatives Thereof.

(FIG. 3C) over days folloWing termination of tWice daily
dosing With 10 mg PBN/kg body Weight. FIG. 3A represents

t-butyl nitrone (PBN), and derivatives thereof. PBN has no

The preferred spin-trapping compounds are ot-phenyl

the level of carbonyl in the soluble protein obtained from
gerbils treated for fourteen days and tested at 1, 3, 7 and 14
days post dosing. FIG. 3B is the time related decrease in

measurable effect on normal or uninjured cells. PBN is the

preferred compound at this time, although a number of
derivatives are also useful, including hydroxy derivatives,
especially 2-, 3- or 4-hydroxy PBN and mono-, di- and

cortical glutamine synthetase (GS) activity after termination
of tWice daily injections of PBN. FIG. 3C demonstrates the
time related decrease in alkaline protease activity folloWing
termination of tWice daily injections of PBN. Each histo
gram is the mean 1 standard error

55

acetoxy derivative, 2-, 3-, or 4-carboxyphenyl t-butyl

of three subjects at

each of the indicated times. The asterisk and dashed line
indicates the old gerbil, untreated control values for each of
the measures.

FIGS. 4A, 4B and 4C are graphs comparing changes in

protein carbonyl (pnollmg protein) (FIG. 4A), glutamine
synthetase (FIG. 4B), and protease activity (% control)
(FIG. 4C) over days folloWing termination of tWice daily
dosing With 32 mg PBN/kg body Weight. FIG. 4A represents
the level of carbonyl in the soluble protein obtained from

trihydroxy tert-butyl nitrone; esters, especially esters Which
release 2-, 3, or 4-hydroxyphenyl t-butyl nitrone such as the

65

nitrone, such as the ethyl derivative, or phenyl hydroxybutyl
nitrone, such as the acetoxy derivative; alkoxyl derivatives,
especially alkoxyl derivatives Which release 2-, or
4-hydroxyphenyl t-butyl nitrone, such as the methyl deriva
tive; and acetamide derivatives, especially acetamide deriva
tives Which release 2-, or 4 aminophenyl t-butyl nitrone,
such as the acetyl derivative; diphenyl nitrone (PPN) and the
analogous diphenyl nitrone derivatives. As used herein,
“PBN” refers to both phenyl t-butyl nitrone and derivatives
thereof, unless otherWise stated.

6,107,315
6

5

The general formula for POBN is:

The general formula for PBN and useful derivatives
thereof is:

O

HC=N—Y

Wherein:

—/ (OR)H
X is phenyl or \ /

/
, Wherein R is H,

10

\
|
/ N

S i
O

15
and n is a Whole integer from 1 to 5; or

Wherein
Y is a tert-butyl group that can be hydroxylated or acetylated
on one or more positions; phenyl; or

/OW
Y is tert-butyl group that can be hydroxylated or acetylated on
one or more positions; phenyl; or

O

/

I

OW
25

—C—OZ, or Z; and S=H, (OR)n, Wherein R is H,

Wherein W is C—CH3, —NH—C—Z, C-OZ, or Z; and
Z is a C1 to C5 straight or branched alkyl group.
n is a Whole number from 1 to 4, or

Other Spin-Trapping Reagents.

35

Other spin-trapping agents can also be used, such as
Z is a C1 to C5 straight or branched alkyl group.

5,5-dimethyl pyrroline N-oxide (DMPO) or ot-(4-pyridyl

1-oxide)-N-tert-butylnitrone (POBN), and spin-trapping
derivatives thereof. Derivatives are made using standard

Indications that the compositions are useful in treating.
The free-radical scavenger compositions are useful in
treating a variety of dysfunctions or disorders characterized
by oxidiZed proteins in the tissues or cells. Oxidation of

techniques, for example, for substitution of the methyl
groups. The general formula for DMPO is:
45

A

cytosolic protein has been demonstrated to occur in a Wide

variety of pathological conditions. Accordingly, compounds
Which have as their fundamental mechanism of action the

/

interference of production of oxidiZed protein should be

B i

useful in the treatment of a Wide variety of diseases having
What appears at ?rst glance to be Widely dissimilar
etiologies, because the fundamental cause of the condition is
oxidation of protein or nucleic acids.
In one embodiment, the spin-trapping agent is adminis

0

wherein A and B are independently CH3, CHZOH,

(OWL.
CHZOW, or

tered to a patient to reverse the damage occurring as a
55

function of age. Preliminary results indicate that there is a
net increase in the oxidation of proteins and the accumula
tion of oxidiZed material in the brain. The development of

senil plaque is also routinely observed in aged patients.

n is an integer from 1 to 5

Other disorders are those resulting from trauma, such as
a bloW to the head, or from drug treatment, for example,
administration of anesthesia or drug abuse, or even as a

wherein W is

result of some types of viral infections.
It has noW been determined that the level of oxidiZed

brain protein appears to be inversely related to performance
—C—OZ, or Z; and

Z is a C1 to C5 straight or branched alkyl group.

in a short term memory task and directly related to risk of
65

stroke-induced damage and behavioral change. Increased
cellular oxidation may result in one or more of the folloW

ing: (a) oxidative damage to cellular proteins could cause a

6,107,315
7

8

change in the regulation of ion channels, there could be a
change in the rate and ef?ciency of signal translation and

useful in treating the retinal damage Which occurs very

frequently in diabetic patients.

membrane depolarization, signi?cant changes in energy

Pre-Surgical Preparation.

?uxes may occur and compromise selective function, the
?delity of RNA transcription may be altered due to oxidative
damage to DNA, RNA translation may be affected either by
oxidation of the RNA or regulatory macromolecules, or the
rate of protein degradation may be altered.

Since the status of the cell and its survival in a hypoxic or

anoxic environment is dependent upon the ability of the cell
to compartmentaliZe metals and handle oxygen in a useful
manner, in contrast to peroxidation, it is expected that these

compounds Will be useful as presurgical preparatory medi
cation to reduce the carbonyl load and improve the enZyme

Any of these changes could negatively impact on the
acquisition consolidation and retrieval of information, even
by interference With a single step in the learning and

10

status of the patient prior to elective surgery. These com

pounds Would also help the cells of the body achieve a

memory process. It is possible that oxidation of cells in a

higher level of enZymatic function, shorten the recuperative

particular brain region could result in acquisition de?cits,

phase, and reduce the likelihood of any interoperative com

plications associated With changes in microcirculation.

Whereas oxidation of a different region could result in output

de?ciency. Considering the number of devastating neurode
generative diseases, including AlZheimer’s disease, this

15

Retroviruses selectively infect certain types of cells, such

treatment could potentially be a tremendous help to people
With these disorders.
Examples of other disorders that can be treated With these

as lymphocytes. An example of a retrovirus that has been the

subject of much research activity is the human immunode
?ciency virus (HIV), Which causes Acquired Immunode?
ciency Syndrome (AIDS). No means for prevention of

compositions include peripheral neuropathy of diabetes,
exercise induced muscle damage and pain, and enhancement

infection has been found, although there have been numer

of cellular response to hormonal signals.
Treatment of Neurodegenerative Disorders.
Several neurodegenerative conditions are most appropri

ately treated by compounds that interfere With protein oxi

ous attempts to ?nd a treatment. Since activation of lym
25

dation. AlZheimer’s disease has been associated With the
accumulation of abnormal oxidiZed proteins or the produc
tion of abnormal proteins in areas that are pathologically

affected. In addition, age related enhancement in protein
oxidation occurs in all cells in the aged individual. PBN and
derivatives thereof have been demonstrated to be useful in
the reduction in protein oxidation and in the increase in the

activity of critical enZymes Within the brain of aged animals.
Since this is a fundamental change in oxidative state, it is

likely that PBN and other related compounds Would be

Treatment of Viral Infections and In?ammatory Disor
ders.

35

useful When given chronically to individuals Who are in the

phocytes is associated With the oxidation of protein and
activation of lymphocytes is required prior to release of
neWly formed viruses, it is expected that administration of
these compositions Will inhibit infection and replication of
lymphocytes by the viruses. The activation of the T-4
lymphocyte is associated With a cascade of biochemical
intracellular changes, one of Which is the production of
oxidiZed protein. If PBN related compounds can block
protein oxidation in the abnormal process then it is possible
that PBN or other spin-trappin compounds could in fact
interfere With the process of viral replication and/or dissemi
nation of the virus from the host cell (T-4 lymphocyte),
thereby acting as a virustatic agent by preventing the T-4

early phases, or possibly in the late phases, of AlZheimer’s

lymphocyte from releasing the neWly formed viruses. This

disease. In addition, multi-infarct dementias should be treat

Would be analogous to the use of isoniaZid (INH) in the

able With these compounds, since they also deal With
ischemia reperfusion oxidation issues.

static in that it reduced the infectivity and spread of the

treatment of tuberculosis. At loW doses INH is a tubercula

tuberculosis, thereby effectively protecting the patient from

Senile dementia has not been directly evaluated for

pulmonary damage.

ischemia reperfusion etiology or protein oxidation, hoWever,
it is likely that senile dementia Would also be treatable With
these compounds. This is based on the hypothesis that
advanced age is associated With increased production of
oxidiZed protein. In progeria, a unique condition in Which
aging is accelerated, Stadtman and colleagues at the NIH

It is important to note that the effects of the spin-trapping
compounds occur in animals that have a base-level of
45

have demonstrated that there is a marked increase in the

carbonyl formation Which appears to be necessary for post
translational processes. Old animals have a signi?cantly
elevated level of carbonyl protein Which is associated With
decreased enZymatic function relative to young control

base-level of oxidiZed protein even in young adult subjects

animals. When young control animals are given the exact

With progeria, as reported by Oliver, et al., J. Biol. Chem.
262, 5488—5491 (1987) and Starke-Reed and Oliver,Arch.

same dosage regimen, there is no signi?cant change in
enZyme activity nor is there signi?cant change in protein
carbonyl. Thus the PBN and related spin-trapping com

Biochem. Biophys. 275, 55 9—567 (1989). While this is a rare
condition it should also be treatable With these composi
tions.
Another condition Which is likely to be associated With

pounds are not likely to interfere With fundamental pro
55

oxidative damage arising from microcirculatory dif?culties
is the diabetic peripheral neuropathies and vascular change.

and enZymatic damage. Spin-trapping compounds are effec
tive in animal models in reducing the protein oxidation and
improving enZymatic function. This occurs in preparations
in Which the abnormal oxidiZed protein is modi?ed and
protected but the normal post translational oxidation is

These are tragic conditions in Which amputation is eventu
ally necessary in order to save the patient. While these
compounds are not likely to improve vascular How they are

likely to reduce the impact of transient changes in vascular
?oW Which result in oxidation and damage to the peripheral
nerves and also in damage to the skeletal muscle Which is
often associated With the condition called exercise induced
or intermittent claudication. If the retinopathy associated
With diabetes is also an ischemia reperfusion microcircula

tion problem, then the spin-trapping compounds Will be

cesses that are necessary for the normal cellular function.
In conclusion, a number of clinical conditions appear to
have as their fundamental cause oxidation of cellular protein

alloWed to occur. This Would suggest that PBN does not

interfere With the normal necessary oxidation of proteins

folloWing synthesis.
65

Effective Dosages of PBN.
Exemplary dosages of PBN range from 0.1 to 10 mg/kg
of body Weight in animals. The effective dosage of PBN in

6,107,315
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humans is expected to be between approximately 1 and 10

sucrose or saccharin; or a ?avoring agent such as

mg/70 kg body Weight. Toxicity tests have demonstrated that
the compound is completely innocuous, With such loW

peppermint, methyl salicylate, or orange ?avoring. When
the dosage unit form is a capsule, it can contain, in addition
to material of the above type, a liquid carrier. In addition,
dosage unit forms can contain various other materials Which

toxicity that it Was not possible to determine an LDSO.
In the preferred application, the PBN is administered to a

patient suffering from memory loss or other symptoms
frequently associated With aging. Optimum results are gen
erally observed after tWo Weeks of daily or tWice daily oral
administration. The compositions can also be effectively
administered prior to, during or shortly after surgery, and
prevent or decrease the extent of cellular damage resulting

modify the physical form of the dosage unit, for example,
coatings of sugar, shellac, or other enteric agents.
The present invention Will be further understood With
10

reference to the folloWing non-limiting examples demon
strating methods for determining effectiveness of PBN
administration for treatment or prevention and/or reversal of

symptoms associated With aging.

from either the trauma or anesthesia.

Since the trapping of endogenous free radicals is speci?c
for only those cells that have been exposed to the conditions
that result in the production of free radicals, the traps have

EXAMPLE 1
15

little or no effect on normal cells. The bene?cial effects

occur only in injured cells, and do not require the presence

of speci?c receptors, speci?c enZymes, and/or speci?c cell
types.

brain protein has previously been demonstrated in gerbils.
Many other psychiatric and neurological conditions have

Methods of Administration of PBN.

The PBN is preferably administered systemically, most
preferably orally, since this is the most rapid and ef?cient

been proposed to be the result of oxidation. Among these
conditions, cellular aging has been associated With oxygen
radicals and the accumulation of proteins. The level of

means for delivering the active compound to the site of free
radical generation. The PBN may be administered at once,
or may be divided into a number of smaller doses to be 25

administered at varying intervals of time. Other methods of
administration can also be used, including subcutaneous,
intravenous, and intraperitoneal administration. The concen

depend on absorption, inactivation, and excretion rates of
the drug as Well as other factors knoWn to those skilled in the
art. The effective dosage may also be determined based on

glutamine synthetase activity and decreased alkaline pro

35

radical generation. It is to be noted that dosage values Will
also vary With the condition of the patient being treated. It
is to be further understood that for any particular subject,

signi?cantly greater numbers of errors in a test of short-term
demonstrate that the functional de?cits that occur as a result

of aging may be associated With increased protein oxidation
and decreased brain enZyme activities.
This system has been used to demonstrate the effective
ness of PBN in restoring young brain enZyme levels and

ment of the person administering or supervising the admin
istration of the compositions, and that the concentration
ranges set forth herein are exemplary only and are not
intended to limit the scope or practice of the claimed

short term memory to old animals. The results are shoWn in
45

A preferred mode of administration of the active com

FIGS. 1 through 5, as folloWs. Young gerbils Were obtained

from Tumblebrook Farms, West Brook?eld, Mass., Weigh
ing 50—60 grams and age three to four months. Control

pound is in a form for oral delivery. Oral compositions Will

gerbils Were given saline. Animals Were killed by decapita
tion and their brains removed for analysis.
FIG. 1A is a graph of the percent alkaline protease in
young (three to four month old) gerbils, old (tWelve to
?fteen month old retired breeder) gerbils, old gerbils admin
istered 0.1 ml saline tWice daily (b.i.d.), and old gerbils
administered 10 mg PBN/kg body Weight bid. for fourteen

generally include an inert diluent or an edible carrier.

Preferred pharmaceutical carriers for intravenous adminis
tration are saline or phosphate buffered saline at physiologi

cal pH. Since PBN degrades at pH less than approximately
3 to 4, it is preferred to administer the PBN at a pH of 4 or
higher, or in combination With food, a buffering agent, or in
an enteric coating. For oral delivery, the PBN may be
55

days.
The results demonstrate that PBN is effective in restoring
alkaline protease levels in old animals to those levels present
in young animals.
FIG. 2A is a graph of the changes in protein oxidation
from brains of young and senescent gerbils, plotting nmol

microencapsulated, entrapped in liposomes, in solution or
suspension,alone or in combination With a substrate immo
biliZing material such as starch or poorly absorbable salts

such as immodium. Pharmaceutically compatible binding
agents can be included as part of the composition. The
tablets or capsules may contain, for example, any of the
folloWing ingredients, or compounds of a similar nature: a
binder such as microcrystalline cellulose, gum tragacanth or
gelatin; an excipient such as starch or lactose, a disintegrat
ing agent such as alginic acid, Primogel®, or corn starch; a
lubricant such as magnesium stearate or Sterotes; a glidant
such as colloidal silicon dioxide; a sWeetening agent such as

protease activity of retired breeders, compared to young
adult gerbils. Consistent With the age-related increase in
protein oxrdation and enZyme damage, retired gerbils made
memory, compared to young adult gerbils. These studies

speci?c dosage regimens should be adjusted over time
according to the individual need and the professional judg

enclosed in capsules, compressed into tablets,

tease activity and radial arm maZe performance in young

tease activity. In contrast, there Was no change in acid

that amount required to prevent or reverse predisposition of

composition.

oxidiZed protein, glutamine synthetase activity, brain pro
adult and retired breeder gerbils have noW been compared
and demonstrate that there is a direct relationship betWeen
the age of the subject and the level of oxidiZed brain protein,
as measured using a protein carbonyl assay. Increased levels
of protein carbonyl Were associated With decreased

tration of active compound in the drug composition Will

the cells to damage resulting from depletion of ATP (as
demonstrated by in vivo NMR) and damage from free

Determination of Brain EnZyme Levels in Old
Versus Young Gerbils Treated With PBN
Acorrelations betWeen the duration of ischemia and either
the change in spontaneous behavior or the level of oxidiZed

protein carbonyl/mg protein versus days of treatment With
PBN. The gerbils Were given tWice daily injections of 32
mg/kg PBN for fourteen days. Animals Were killed at one,

three, seven and fourteen days and protein carbonyl levels
65

determined.
As can be seen in the ?gure, there is no change in the level

of oxidiZed protein of young gerbils treated for up to 14 days

6,107,315
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With PBN. This indicates that the level of oxidized protein
is likely to be a natural and necessary post translational

as effective as administration of 32 mg PBn/kg body Weight

in restoring young enZyme levels. The appropriate dosages
and full range of effective dosages for other species of

effect, for example, if after synthesis of the protein, the
protein is activated by a modi?cation involving carbonyl

animals can be determined using a similar methodology.

oxidation. In contrast to the carbonyl level seen in young

The time related changes in protein oxidation and enZyme

animals, control aged animals (15 months of age) have a
marked increase of carbonyl content. This increased carbo
nyl content is responsive to treatment With PBN. Multiple
days of treatment With PBN results in a progressive reduc
tion in the level of protein carbonyl to the level seen in
young animals.

activity folloWing termination of tWice daily dosing With
either 10 mg PBN/kg (FIGS. 3A, B, and C) or 32 mg
PBN/kg (FIGS. 4A, B, and C) are also shoWn by these
?gures. The results demonstrate that the effect of the PBN is
10

The level of protein carbonyl reduction (oxidiZed protein
burden of neurons in the brain) is only to the level of the
normal young gerbil brain. Neither the levels in the young
gerbil brain nor the levels in the senescent gerbil brain can
be further reduced beyond this level. This observation
supports the hypothesis that there is a necessary level of
oxidation that occurs in cells in normal animals, Which is
required for cells to have “normal function”, and that control

tWice daily With the PBN, although the PBN itself has a
half-life of three hours. At seven days, the enZyme levels are

altered by approximately 50%.
At fourteen days, the oxidiZed enZymes have returned to
15

approximately their pre-treatment levels.
EXAMPLE 3

aged animals (15 months of age) have a marked increase of
carbonyl content. This increased carbonyl content is respon
sive to treatment With PBN, The ability of PBN to reduce the
protein carbonyl load of cells also indicates that this is an

unaltered one to three days after termination of treatment

20

Demonstration of Correlation BetWeen Effect of
PBN on Brain EnZymes and Memory

FIG. 5 demonstrates that there is a functional counterpart
to such treatment. Young and old gerbils Were tested in a
radial arm maZe test for spacial and short term memory.
Animals Were placed in the central hub of a eight armed
if the process is interrupted.
25
radial maZe and given access to explore all eight arms of the
FIG. 2B compares the levels of glutamine synthetase (gs)
radial arm maZe. When the animal completed the test of
in young and old animals and evaluates the effects of daily
active oxidation process Which occurs at a regular or pre
dictable rate and that there are mechanisms existent Within
the cells of the brain Which can remove this oxidiZed protein

exploring each of the eight arms, the animal Was removed
from the maZe. The number of times that the animals

administration of PBN on the speci?c activity of the
enZyme. This particular enZymatic marker has been selected
because it is a highly sensitive protein to oxidation and
because it is a metalloprotein that has bound to it metal
Which may participate in the generation of free radicals if the
metal is dissociated With its binding site. Glutamine syn

30
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protein oxidation.
As shoWn in FIG. 2B, the level of glutamine synthetase is
loWer in old gerbils (1.2) than in young adult gerbils (2.1).
This is consistent With previous studies in Which increases in

the level of the carbonyl protein (oxidiZed protein in cells)

as an error. Under ideal conditions animals Will enter each
one of the eight arms but not reenter any of the arms. In

many cases young adult gerbils (young) entered each of the
arms Without reentering any of the arms. The time required

thetase activity has been used by Stadman and colleagues
(Oliver, et al., Proc. Natl. Aca'. Scie. USA 87, 5144—5147
(July 1990)) as a marker enZyme for alterations folloWing

reentered arms that had been previously entered Was counted

40

to enter all eight arms Was also recorded but did not appear

to determine the efficiency of the short term memory task. As
can be seen in FIG. 5, young gerbils made an average of 2.83
errors during the test session. In contrast old gerbils made an
average of 6.82 errors, Which is a highly signi?cant differ
ence betWeen the tWo groups.

Young adult gerbils exposed to a period of transient

is associated With a decrease in glutamine synthetase activ

ischemia, Which is also an oxidiZing process, make a sub

ity. In particular, if the glutamine synthetase enZyme is
puri?ed and the carbonyl content of that enZyme is

stantial number of errors With an average value of 15 errors

evaluated, there is a marked increase in the level of oxidiZed

in such a test session. During the post ischemic period, there
is a marked build up of carbonyl protein and reduction in
glutamine synthetase activity similar to that Which is seen in

protein in the presence of loWered glutamine synthetase
activity. As also demonstrated in FIG. 2B, repeated admin

45

istration of PBN in young gerbils had no effect on glutamine

aging.

synthetase activity, providing further evidence that the level
of carbonyl is associated With normal function and chronic

Treatment of gerbils for seven days results in a marked
alteration in the number of errors seen With old gerbils.

administration of PBN has no effect on either the level of
carbonyl or on the marker enZyme activity. In contrast to the

Young gerbils given PBN for seven days Were not signi?
cantly different from control gerbils Whereas the old gerbils

young gerbils, old gerbils given daily injections of PBN
shoW a time related increase in glutamine synthetase activity

that parallels the reduction in protein carbonyl content,
indicating that the reduction in oxidiZed protein burden of
cells is associated With a recovery of the enZymatic activity
to the normal level seen in young adult gerbils.

55

reduction in protein carbonyl and the increase in glutamine
synthetase activity folloWing chronic PBN treatment. This
functional counterpart is demonstrated by the number of

It is important to note that there is no increase in enZy

matic activity above that seen in young adult gerbils. Thus

errors seen in a short term spacial memory task, the radial

the treatment With PBN reverses the effect of aging on

arm maZe. It should be noted that the radial arm maZe test

enZymatic activity but does not result in an activation of
enZyme activity that exceeds the normal values.

does not require any food reinforcement or any other reWard
associated With the test. Naive animals are placed into the

EXAMPLE 2

radial arm maZe, are tested once and these differences are
reliable on retest.

Determination of Residual Effect of PBN on

Reduction of Brain EnZyme Levels
As shoWn in FIGS. 3A, 3B, and 3C, as compared With
FIGS. 4A, 4B, and 4C, administration of 10 mg PBN/kg is

given PBN for seven days shoWed a marked reduction in the
number of errors and returned to the range of performance
seen With control young gerbils. Thus, there is a functional
counterpart to the biochemical changes that are seen in that

65

Modi?cations and variations of the method and compo
sition for the treatment of aging Will be obvious to those

skilled in the art from the foregoing detailed description.

6,107,315
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Such modi?cations and variations are intended to come

Within the scope of the appended claims.
We claim:

1. A method of treating peripheral neuropathy in a patient

suffering from peripheral neuropathy comprising adminis
tering to a patient an effective peripheral neuropathy treating
amount of a composition having as the active agent a

compound selected from the group consisting of alpha

phenyl t-butyl nitrone (PBN); 5,5-dimethyl pyrroline
N-oXide (DMPO); alpha-(4-pyridyl 1-oXide)-N-tert
butylnitrone (POBN) and derivatives thereof selected from
the group consisting of hydroXy PBNs, POBNs and
DMPOs; PBN, POBN and DMPO esters; acetoXy PBNs,
POBNs and DMPOs; alkyl PBNs, POBNs and DMPOs;
alkoXy PBNs, POBNs and DMPOs; and phenyl PBNs,
POBNs and DMPOs having spin trapping activity in vivo in
tissue; and
a pharmaceutically acceptable carrier therefor.

10

15

or Z; and
Z is a C1 to C5 straight or branched alkyl group; or

(b) at least one compound of formula (II)

(11)

2. The method of claim 1 Wherein the active agent is PBN.
3. The method of claim 1 Wherein the active agent is
provided in a dosage of betWeen 1 to 300 mg/kg body

Weight.
4. The method of claim 1 Wherein the active agent is
provided in combination With a pharmaceutical carrier
selected from the group consisting of microspheres,

25

liposomes, immobiliZing substrates, polymeric matrices and
buffering agents.

O

wherein A and B are independently CH3, CHZOH,

5. A method of treating peripheral neuropathy in a patient

CHZOW, or

suffering from peripheral neuropathy comprising adminis
tering to said patient an effective peripheral neuropathy
treating amount of a composition having as the active agent
a compound selected from the group consisting of
(a) at least one compound of formula (I):

@ (OW)n, and
35

(I)
H

/

Wherein n is an integer from 1 to 5,

O'

C — N+
\

X

Y

Wherein:
X is phenyl or
45

Z is a C1 to C5 straight or branched alkyl group;
(c) at least one compound of formula (III):

—/ (OR)11

(III)
Wherein R is H,

55

and n is a Whole integer from 1 to 5; or

65

Y is a tert-butyl group that can be hydroXylated or
acetylated on one or more positions; phenyl; or

Wherein
Y is a tert-butyl group that can be hydroXylated or
acetylated on one or more positions; phenyl or

6,107,315
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10. The method of claim 6 Wherein Y is phenyl.
11. The method of claim 6 Wherein Y is

5

wherein W is
O

O

0

||

||

||

12. The method of claim 5 Wherein X is

10

NH—C—Z—, —C—CH3, —C—OZ,

or Z; and

S=H, (OR)n, wherein R is H,
15
O

and Y is a tert-butyl group.
13. The method of claim 5 Wherein said active agent is

_

||

/0

Z—C—, Z, or —CH=N+\

de?ned by formula (II).
Y

14. The method of claim 13 Wherein A and B are selected
20

15. The method of claim 13 Wherein at least one of A and
B is

Wherein Y is as de?ned above,
n is a Whole number from 1 to 4, or

II

from the group consisting of CH3, CHZOH and CHZOW.

25

NH— C— Z; and

Z is a C1 to C5 straight or branched alkyl group;

30

(d) at least one other alpha-phenyl t-butyl nitrone (PBN)

16. The method of claim 5 Wherein said active agent is

de?ned by formula (III).

derivative selected from the group consisting of

17. The method of claim 16 Wherein Y is a tert-butyl

hydroXy PBNs, PBN esters, acetoXy PBNs, alkyl
PBNs, alkoXy PBNs and phenyl PBNs having spin

group that can be hydroXylated or acetylated on one or more

trapping activity in vivo in tissue;
(e) at least one other alpha-(4-pyridyl 1-oXide)-N-tert
butylnitrone (POBN) derivative selected from the
group consisting of hydroXy POBNs, POBN esters,
acetoXy POBNs, alkyl POBNs, alkoXy POBNs and
phenyl POBNs having spin trapping activity in vivo in
tissue; and

positions.
35
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(f) at least one other 5,5-dimethyl pyrroline N-oXide
(DMPO) derivative selected from the group consisting

of hydroXy DMPOs, DMPO esters, acetoXy DMPOs,
alkyl DMPOs, alkoXy DMPOs and phenyl DMPOs
having spin trapping activity in vivo in tissue;

18. The method of claim 16 Wherein Y is phenyl.
19. The method of claim 16 Wherein Y is

20. The method of claim 16 Wherein S is (OR)n.
21. The method of claim 16 Wherein S is
45

optionally in association With a pharmaceutically accept
able carrier.
6. The method of claim 5 Wherein said active agent is

de?ned by formula
7. The method of claim 6 Wherein X is

50

22. The method of claim 5 Wherein said active agent is

selected from the group consisting of hydroXy PBNs, PBN

esters, acetoXy PBNs, alkyl PBNs, alkoXy PBNs and phenyl
PBNs.
55

23. The method of claim 5 Wherein said active agent is

selected from the group consisting of hydroXy POBNs,

POBN esters, acetoXy POBNs, alkyl POBNs, alkoXy
POBNs, and phenyl POBNs.

8. The method of claim 6 Wherein X is

24. The method of claim 5 Wherein said active agent is
60

selected from the group consisting of hydroXy DMPOs,

DMPO esters, acetoXy DMPOs, alkyl DMPOs, alkoXy
DMPOs and phenyl DMPOs.
25. A method according to claim 5 Wherein said active
agent is PBN.
9. The method of claim 6 Wherein Y is a tert-butyl group 65
that can be hydroXylated or acetylated on one or more

positions.

26. A method according to claim 5 Wherein said com

pound is provided in combination With a pharmaceutical
carrier selected from the group consisting of microspheres,

6,107,315
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liposomes, immobilizing substrates, polymeric matrices,

and n is a Whole integer from 1 to 5; or

and buffering agents.
27. A method according to claim 5 Wherein said com

pound is administered in a dosage of from 1 to 300 mg/kg

body Weight.
28. A method of treating intermittent claudication in a

Y is a tert-butyl group that can be hydroXylated or

patient suffering from intermittent claudication comprising
administering to said patient an effective intermittent
claudication-treating amount of a composition having as the
active agent a compound selected from the group consisting

of alpha-phenyl t-butyl nitrone (PBN); 5,5-dimethyl pyrro
line N-oXide (DMPO); alpha-(4-pyridyl 1-oXide)-N-tert

acetylated on one or more positions; phenyl; or
10

-——/OW;

\ /
15

butylnitrone (POBN) and derivatives thereof selected from
the group consisting of hydroXy PBNs, POBNs and
DMPOS; PBN, POBN and DMPO esters; acetoXy PBNs,
POBNs and DMPOs; alkyl PBNs, POBNs and DMPOs;
alkoXy PBNs, POBNs and DMPOs; and phenyl PBNs,
POBNs and DMPOs having spin trapping activity in vivo in
tissue; and
a pharmaceutically acceptable carrier therefor.
29. The method of claim 28 Wherein the active agent is

Wherein W is
o

o

0

||

||

H

or Z; and
Z is a C1 to C5 straight or branched alkcyl group; or
25

(b) at least one compound of formula (II):

PBN.

<11)

30. The method of claim 28 Wherein the active agent is
provided in a dosage of betWeen 1 to 300 mg/kg body

.13

Weight.

N

B

31. The method of claim 28 Wherein the active agent is
provided in combination With a pharmaceutical carrier

selected from the group consisting of microspheres,

liposomes, immobiliZing substrates, polymeric matrices and
buffering agents.

35

Wherein A and B are independently CH3, CHZOH,
CHZOW, or

32. A method of treating intermittent claudication in a

(OW)n,

patient suffering from intermittent claudication comprising
administering to said patient an effective intermittent
claudication-treating amount of a composition having as the
active agent a compound selected from the group consisting
of

(a) at least one compound of formula (I):
45

and
Wherein n is an integer from 1 to 5,
W is

(I)
H

/

O'

O

O

0

C = N+
\

X

Y

or Z;

Wherein:
X is phenyl or

Z is a C1 to C5 straight or branched alkyl group;

(c) at least one compound of formula (III):

—/(OR)11>

55

(III)
HC

/ |
{Q

E

65

Wherein
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35. The method of claim 33 Wherein X is

Y is a tert-butyl group that can be hydroXylated or
acetylated on one or more positions; phenyl or

36. The method of claim 33 Wherein Y is a tert-butyl
group that can be hydroXylated or acetylated on one or more

positions.
37. The method of claim 33 Wherein Y is phenyl.
38. The method of claim 33 Wherein Y is
15

39. The method of claim 32 Wherein X is

25

Wherein Y is as de?ned above,

and Y is a tert-butyl group.
40. The method of claim 32 Wherein said active agent is

n is a Whole number from 1 to 4, or

de?ned by formula (II).
41. The method of claim 40 Wherein A and B are selected

from the group consisting of CH31, CHZOH and CHZOW.
42. The method of claim 40 Wherein at least one of A and
B is

@ (OW)n.

Z is a C1 to C5 straight or branched alkyl group;

(d) at least one other alpha-phenyl t-butyl nitrone (PBN)
derivative selected from the group consisting of

hydroXy PBNs, PBN esters, acetoXy PBNs, alkyl
PBNs, alkoXy PBNs and phenyl PBNs having spin
trapping activity iln vivo in tissue;
(e) at least one other alpha-(4-pyridyl 1-oXide)-N-tert
butylnitrone (POBN) derivative selected from the
group consisting of hydroXy POBNs, POBN esters,

43. The method of claim 32 Wherein said active agent is

de?ned by formula (III).
44. The method of claim 43 Wherein Y is a tert-butyl
group that can be hydroXylated or acetylated on one or more

positions.
45

45. The method of claim 43 Wherein Y is phenyl.
46. The method of claim 43 Wherein Y is

acetoXy POBNs, alkyl POBNs, alkoXy POBNs and
phenyl POBNs having spin trapping activity in vivo in
tissue; and
(f) at least one other 5,5-dimethyl pyrroline N-oXide
(DMPO) derivative selected from the group consisting

of hydroXy DMPOs, DMPO esters, acetoXy DMPOS,
alkyl DMPOs, alkoXy DMPOs and phenyl DMPOs
having spin trapping activity in vivo in tissue;
optionally in association With a pharmaceutically accept

47. The method of claim 43 Wherein S is (OR)n.
48. The method of claim 43 Wherein S is
55

able carrier.
33. The method of claim 32 Wherein said active agent is

de?ned by formula
49. The method of claim 42 Wherein said active agent is

34. The method of claim 33 Wherein X is

selected from the group consisting of hydroXy PBNs, PBN

esters, acetoXy PBNs, alkyl PBNs, alkoXy PBNs and phenyl
PBNs.

50. The method of claim 42 Wherein said active agent is
65

selected from the group consisting of hydroXy POBNs,

POBN esters, acetoXy POBNs, alkyl POBNs, alkoXy
POBNs, and phenyl POBNs.

6,107,315
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51. The method of claim 42 wherein said active agent is

Wherein R is H,

selected from the group consisting of hydroXy DMPOS,

DMPO esters, acetoXy DMPOS, alkyl DMPOS, alkoXy

O

DMPOs and phenyl DMPOs.
52. A method according to claim 42 Wherein said active
agent is PBN.

H

/O_
\Y

—Z—C—, or Z; or —CH=NJr

53. A method according to claim 42 Wherein said com

pound is provided in combination With a pharmaceutical
carrier selected from the group consisting of microspheres,

and n is a Whole integer from 1 to 5; or

liposomes, immobilizing substrates, polymeric matrices,
and buffering agents.
54. A method according to claim 42 Wherein said com

pound is administered in a dosage of from 1 to 300 mg/kg

body Weight.
55. A method of treating exercise-induced muscle damage
in a patient suffering from exercise-induced muscle damage
comprising administering to said patient an effective

15

Y is a tert-butyl group that can be hydroXylated or
acetylated on one or more positions; phenyl; or

exercise-induced muscle damage treating amount of a com

position having as the active agent a compound selected

from the group consisting of alpha-phenyl t-butyl nitrone

—

/

(PBN); 5,5-dimethyl pyrroline N-oXide (DMPO); alpha-(4

OW;

pyridyl 1-oXide)-N-tert-butylnitrone (POBN) and deriva
tives thereof selected from the group consisting of hydroXy
PBNs, POBNs and DMPOs; PBN, POBN and DMPO esters;

acetoXy PBNs, POBNs and DMPOs; alkyl PBNs, POBNs
and DMPOs; alkoXy PBNs, POBNs and DMPOS; and

25

Wherein W is

phenyl PBNs, POBNs and DMPOs having spin trapping
activity in vivo in tissue; and
a pharmaceutically acceptable carrier therefor.

O

O

||

||

C—CH3,

56. The method of claim 53 Wherein the active agent is

0

||

NH-C-Z,

C-OZ,

PBN.

57. The method of claim 53 Wherein the active agent is
provided in a dosage of betWeen 1 to 300 mg/kg body

Weight.
58. The method of claim 53 Wherein the active agent is
provided in combination With a pharmaceutical carrier

or Z; and
Z is a C1 to C5 straight or branched alkyl group; or
35

(b) at least one compound of formula (II):

selected from the group consisting of microspheres,
(11)

liposomes, immobiliZing substrates, polymeric matrices and
buffering agents.

.13

59. A method of treating exercise-induced muscle damage
in a patient suffering from exercise-induced muscle damage
comprising administering to said patient an effective

N

B i

exercise-induced muscle damage treating amount of a com

position having as the active agent a compound selected
from the group consisting of
(a) at least one compound of formula (I):

45

wherein A and B are independently CH3, CHZOH,
CHZOW, or

(I)
H

@(OW)W and

O

\C= N/+\

/
X

Y
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Wherein:
X is phenyl or

Wherein n is an integer from 1 to 5,
W is
O

O

O

—/ (OR)n>
or Z;

Z is a C1 to C5 straight or branched alkyl group;

6,107,315
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61. The method of claim 60 Wherein X is

(c) at least one compound of formula (III):

(III)

(ORL.

5

Q

'

62. The method of claim 60 Wherein X is
10

04-2
wherein

15

Y is a tert-butyl group that can be hydroXylated or
acetylated on one or more positions; phenyl or

63. The method of claim 60 Wherein Y is a tert-butyl
group that can be hydroXylated or acetylated on one or more

positions.
64. The method of claim 60 Wherein Y is phenyl.
65. The method of claim 60 Wherein Y is

o”

Wherein W is
25

66. The method of claim 59 Wherein X is
0

@wt.

30

35

and Y is a tert-butyl group.

67. The method of claim 59 Wherein said active agent is

de?ned by formula (II).

Wherein Y is as de?ned above,
n is a Whole number from 1 to 4, or

68. The method of claim 67 Wherein A and B are selected

40 from the group consisting of CH3, CHZOH and CHZOW.
69. The method of claim 67 Wherein at least one of A and
B is
45

@ (OW)11

Z is a C1 to C5 straight or branched alkyl group;

(d) at least one other alpha-phenyl t-butyl nitrone (PBN)
derivative selected from the group consisting of

hydroXy PBNs, PBN esters, acetoXy PBNs, alkyl
PBNs, alkoXy PBNs and phenyl PBNs having spin
trapping activity in vivo in tissue;
(e) at least one other alpha-(4-pyridyl 1-oXide)-N-tert
butylnitrone (POBN) derivative selected from the
group consisting of hydroXy POBNs, POBN esters,

70. The method of claim 59 Wherein said active agent is

de?ned by formula (III).
71. The method of claim 70 Wherein Y is a tert-butyl
group that can be hydroXylated or acetylated on one or more
55

acetoXy POBNs, alkyl POBNs, alkoXy POBNs and
phenyl POBNs having spin trapping activity in vivo in
tissue; and

.

.

positions.
72. The method of claim 70 Wherein Y is phenyl.

(f) at least one other 5,5-dimethyl pyrroline N-oXide
(DMPO) derivative selected from the group consisting

73. The method of claim 70 Wherein Y is

of hydroXy DMPOs, DMPO esters, acetoXy DMPOs,
alkyl DMPOs, alkoXy DMPOs and phenyl DMPOs
having spin trapping activity in vivo in tissue;
optionally in association With a pharmaceutically accept
able carrier.
60. The method of claim 59 Wherein said active agent is

de?ned by formula

65

74. The method of claim 70 Wherein S is (OR)n.

6,107,315
25
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(a) at least one compound of formula (I):

75. The method of claim 70 wherein S is

(I)

H C=N4O
\

X

76. The method of claim 59 Wherein said active agent is

selected from the group consisting of hydroXy PBNs, PBN

10

Y

Wherein:
X is phenyl or

esters, acetoXy PBNs, alkyl PBNs, alkoXy PBNs and phenyl
PBNs.

—/(OR)n

77. The method of claim 59 Wherein said active agent is

selected from the group consisting of hydroXy POBNs,

POBN esters, acetoXy POBNs, alkyl POBNs, alkoXy
POBNs, and phenyl POBNs.

15

Wherein R is H,

78. The method of claim 59 Wherein said active agent is

selected from the group consisting of hydroXy DMPOs,

DMPO esters, acetoXy DMPOs, alkyl DMPOs, alkoXy
DMPOs and phenyl DMPOs.
79. A method according to claim 59 Wherein said active
agent is PBN.
80. A method according to claim 59 Wherein said com

and n is a Whole integer from 1 to 5; or
25

pound is provided in combination With a pharmaceutical
carrier selected from the group consisting of microspheres,

liposomes, immobilizing substrates, polymeric matrices,
and buffering agents.
81. A method according to claim 59 Wherein said com
Y is a tert-butyl group that can be hydroXylated or

pound is administered in a dosage of from 1 to 300 mg/kg

acetylated on one or more positions; phenyl; or

body Weight.
82. A method of inhibiting in?ammation arising from
viral infection in a patient suffering from in?ammation

35

arising from viral infection comprising administering to said
patient an effective in?ammation-inhibiting amount of a

composition having as the active agent a compound selected

from the group consisting of alpha-phenyl t-butyl nitrone

Wherein W is

(PBN); 5,5-dimethyl pyrroline N-oXide (DMPO); alpha-(4
pyridyl 1-oXide)-N-tert-butylnitrone (POBN) and deriva

O

acetoXy PBNs, POBNs and DMPOS; alkyl PBNs, POBNs
and DMPOs; alkoXy PBNs, POBNs and DMPOs; and phe

or Z; and
Z is a C1 to C5 straight or branched alkyl group; or

(b) at least one compound of formula (II):

in vivo in tissue; and

a pharmaceutically acceptable carrier therefor.
83. The method of claim 82 Wherein the active agent is

(11)

.13

PBN.

84. The method of claim 82 Wherein the active agent is
provided in a dosage of betWeen 1 to 300 mg/kg body

N

wherein A and B are independently CH3, CHZOH,
CHZOW, or

liposomes, immobiliZing substrates, polymeric matrices and
buffering agents.

O/ (OW)n,

86. A method of inhibiting in?ammation arising from
viral infection in a patient suffering from in?ammation
arising from viral infection comprising administering to a
composition having as the active agent a compound selected
from the group consisting of

B i

55

85. The method of claim 82 Wherein the active agent is
provided in combination With a pharmaceutical carrier
selected from the group consisting of microspheres,

patient an effective in?ammation-inhibiting amount of a

0

45

nyl PBNs, POBNs and DMPOs having spin trapping activity

Weight.

O

I
I
I
C—CH3, NH—C—Z, C—OZ,

tives thereof selected from the group consisting of hydroXy
PBNs, POBNs and DMPOs; PBN, POBN and DMPO esters;

65

and
Wherein n is an integer from 1 to 5,

6,107,315
28
of hydroXy DMPOs, DMPO esters, acetoXy DMPOs,
alkyl DMPOs, alkoXy DMPOs and phenyl DMPOs
having spin trapping activity in vivo in tissue;
optionally in association With a pharmaceutically accept
able carrier.
87. The method of claim 86 Wherein said active agent is

de?ned
88. The
by method
formula of claim 87 Wherein X is

Z is a C1 to C5 straight or branched alkyl group;
(c) at least one compound of formula (III):
10

(III)

15

89. The method of claim 87 Wherein X is
0

||

04-2
90. The method of claim 87 Wherein Y is a tert-butyl

Wherein

group that can be hydroXylated or acetylated on one or more

Y is a tert-butyl group that can be hydroXylated or

positions.

acetylated on one or more positions; phenyl or

91. The method of claim 87 Wherein Y is phenyl.
92. The method of claim 87 Wherein Y is

3O

Wherein W is

93. The method of claim 86 Wherein X is
35

and Y is a tert-butyl group.
94. The method of claim 86 Wherein said active agent is

de?ned by formula (II).
95. The method of claim 94 Wherein A and B are selected
45

from the group consisting of CH3, CHZOH and CHZOW.
96. The method of claim 94 Wherein at least one of A and
B is

Wherein Y is as de?ned above,
n is a Whole number from 1 to 4, or

Q
Z is a C1 to C5 straight or branched alkyl group;

(d) at least one other alpha-phenyl t-butyl nitrone (PBN)

97. The method of claim 86 Wherein said active agent is
55

98. The method of claim 97 Wherein Y is a tert-butyl

derivative selected from the group consisting of

group that can be hydroXylated or acetylated on one or more

hydroXy PBNs, PBN esters, acetoXy PBNs, alkyl
PBNs, alkoXy PBNs and phenyl PBNs having spin
trapping activity in vivo in tissue;

positions.
99. The method of claim 97 Wherein Y is phenyl.
100. The method of claim 97 Wherein Y is

(e) at least one other alpha-(4-pyridyl 1-oXide)-N-tert
butylnitrone (POBN) derivative selected from the
group consisting of hydroXy POBNs, POBN esters,

acetoXy POBNs, alkyl POBNs, alkoXy POBNs and
phenyl POBNs having spin trapping activity in vivo in
tissue; and
(f) at least one other 5,5-dimethyl pyrroline N-oXide
(DMPO) derivative selected from the group consisting

de?ned by formula (III).
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101. The method of claim 97 Wherein S is (OR)n.

